Naltrexone implants after in-patient treatment for opioid dependence: Randomised controlled trial

British Journal of Psychiatry

Volumn 194, Issue 6, 2009, Pages 541-546

  Kunøe, Nikolaj ^a   Lobmaier, Philipp ^a   Vederhus, John Kåre ^b   Hjerkinn, Bjørg ^b   Hegstad, Solfrid ^c   Gossop, Michael ^d   Kristensen, Øistein ^b   Waal, Helge ^a  

^a Norwegian Centre for Addiction Research   (Norway)

^b SØRLANDET HOSPITAL   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 BETA NALTREXOL; ALCOHOL; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CODEINE; DIAMORPHINE; DRUG METABOLITE; METHADONE; MORPHINE; NALTREXONE; OPIATE; UNCLASSIFIED DRUG;

ABSTINENCE; ADULT; AFTERCARE; ARTICLE; BLOOD ANALYSIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG BLOOD LEVEL; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG IMPLANT; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE DRUG ABUSE; NECROSIS; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN; RANDOMIZED CONTROLLED TRIAL; SUICIDE ATTEMPT; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NALTREXONE; NARCOTIC ANTAGONISTS; NORWAY; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649207399     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.108.055319     Document Type: Article

References (35)

1. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Arch Gen Psychiatry 1978; 35; 335-340 (Pubitemid 8322956)
2. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; 1: CD001333.
3. Sullivan MA, Rothenberg JL, Vosburg SK, Church SH, Feldman SJ, Epstein EM, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict 2006; 15: 150-159
4. Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B. Naltrexone: a clinical perspective. J Clin Psychiatry 1984; 45: 25-28
5. Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G. A pilot study of naltrexone-accelerated detoxification in opioid dependence. Med J Aust 1999; 171: 26-30. (Pubitemid 29342244)
6. Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev 2000; 19: 41-48
7. Waal H, Aamodt O, Olsen H. [Use of naltrexone in the treatment of young drug addicts.] Tidsskr Nor Laegeforen 2003; 123: 1662-1664
8. Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007; 16: 1285-1294 (Pubitemid 47317017)
9. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-218 (Pubitemid 43213883)
10. Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 2: CD006140. (Pubitemid 351807436)
11. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol 2002; 7: 321-323 (Pubitemid 34848420)
12. Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003; 8: 211-217 (Pubitemid 36859662)
13. Carreno JE, Alvarez CE, San Narciso GL, Bascarán MT, Díaz M, Bobes J, et al. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol 2003; 8: 429-438 (Pubitemid 38102049)
14. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Stood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol 2004; 9: 59-65. (Pubitemid 38608487)
15. Hulse GK, Tait RJ, Comer SD, Sullivan MA, Jacobs IG, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351-357 (Pubitemid 41127163)
16. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implant. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 23-28
17. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy 2007; 2: 35.
18. Waal H, Christophersen AS, Frogopsahl G, Olsen LH, Morland J. [Naltrexone implants - a pilot project.] Tidsskr Nor Laegeforen 2003; 123: 1660-1661
19. Olsen L, Christophersen AS, Frogopsahl G, Waal H, Morland J. Plasma concentrations during naltrexone implant treatment of opiate-dependent patients. Br J Clin Pharmacol 2004; 58: 219-222 (Pubitemid 39044005)
20. Waal H, Frogopsahl G, Olsen L, Christophersen AS, Morland J. Naltrexone implants - duration, tolerability and clinical usefulness. A pilot study. Eur Addict Res 2006; 12: 138-144 (Pubitemid 43909807)
21. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Eur Addict Res 2007; 13: 66-73.
22. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
23. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In Measuring Alcohol consumption: Psychosocial and Biochemical Methods (eds RZ Litten & JP Allen): 41-72. Humana Press, 1992.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
25. Sheehan DV, Lecrubier Y. Mini-International Neuropsychiatric Interview (English version 5.00). University of South Florida, 1998.
26. Kotkevi A, Hargers C. EUROPASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995: 1: 208-210
27. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571
28. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L.et al. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci 1974; 19: 1-15.
29. Pavot W, Diener E, Suh E. The Temporal Satisfaction With Life Scale. J Pers Assess 1998; 70: 340-354 (Pubitemid 28347664)
30. Hegstad S, Khiabani H, Kristoffersen L, Kunøe N, Lobmaier P, Christophersen AS. Drug screening of hair by liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2008; 32: 364-372 (Pubitemid 351879790)
31. Shearer J, White B, Gilmour S, Wodak AD, Dolan KA. Hair analysis underestimates heroin use in prisoners. Drug Alcohol Rev 2006; 25: 425-431 (Pubitemid 44594406)
32. Gossop M, Stewart D, Browne N, Marsden J. Factors associated with abstinence, lapse or relapse to heroin use after residential treatment: protective effect of coping responses. Addiction 2002; 97: 1259-1267
33. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617-1625 (Pubitemid 40471792)
34. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol 2006; 26: 610-625 (Pubitemid 44772738)
35. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007; 27: 507-512 (Pubitemid 47415052)